Nexstim Plc: Share subscriptions based on stock options 2020 and 2023
Company Announcement, Helsinki, 27 October 2026 at 10 AM (EEST)
Nexstim Plc: Share subscriptions based on stock options 2020 and 2023
Nexstim Plc ("Nexstim" or "Company") announces that between 13 May and 30 September 2026, a total of 47,025 Nexstim Plc’s new shares have been subscribed for with the company's stock options 2020 and 2023. For subscriptions made with the stock options 2020 and 2023, the entire subscription price of EUR 153,286.77 will be entered in the reserve for invested unrestricted equity.
After the trade registration the total amount of shares is 8,121,884.
The shares subscribed for under the stock options 2020 and 2023 have been registered in the Trade Register on 2 November 2026, as of which date the new shares will establish shareholder rights.
The shares will be traded in the Nasdaq Helsinki Plc’s First North Growth Market Finland marketplace as an additional lot with the company’s old shares as of 3 November 2026.
The terms and conditions of stock option programs with additional information are available on the company's website at https://www.nexstim.com/investors/.
Further information is available on the website , or by contacting: www.nexstim.com
CEO Mikko Karvinen,
+358 50 326 4101
The Company’s Certified Adviser is DNB Carnegie Investment Bank AB.
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of Major Depressive Disorder (MDD) in adult and adolescent patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode, and as an adjunct for the treatment of adult patients suffering from Obsessive Compulsive Disorder (OCD). In Europe, the NBS 6 system is CE-marked for the treatment of major depression, chronic neuropathic pain as well as post-operative rehabilitation of motor deficits of the upper limb.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit . www.nexstim.com